Printed From:

In this pharmacokinetics/
pharmacodynamics study,
Toujeo® demonstrated a
glucose-lowering effect
that lasted up to 36 hours1

This PK/PD study describes the time course effect following Toujeo® administration.

Consistent blood
glucose levels within
the
ADA-recommended
range of 80-130 mg/dL1-3

This PK/PD study describes the time course effect following Toujeo® administration.

Study Description
Clamp Study 11,2

Design
Double-blind, randomized single-center, 2-treatment, 2-period, 2-sequence crossover euglycemic clamp study. Evaluated Toujeo® PK/PD at steady state compared with Lantus®.

Population
Patients with type 1 diabetes mellitus (T1DM) (N=30).

Treatment
Once-daily injections for 8 consecutive days in each treatment period.
On day 8, the dose was followed by a 36-hour euglycemic clamp. Toujeo® in the first treatment period, followed by a washout period and then Lantus® treatment in the second period (or vice versa).

ADA, American Diabetes Association; BG, blood glucose; GIR, glucose infusion rate; PD, pharmacodynamics; PK, pharmacokinetics.

Read the Toujeo® PK/PD study publications at PubMed.gov

Graphic demonstrates key differences in the formulation of Toujeo® versus that of Lantus®: a reduced injection volume for the same number of units and a smaller precipitate.




For illustration purposes only.

References:

  1. Toujeo Prescribing Information.
  2. American Diabetes Association. Diabetes Care. 2017;40(suppl 1):S1-S135.
  3. Becker RHA, Dahmen R, Bergmann, Lehmann A, Jax T, Heise T. Diabetes Care. 2015;38(4):637-643.
  4. Maiorino Ml, Petrizzo M, Capuano A, Giugliano D, Esposito K. Exp Opin Biol Ther. 2014;14(6):799-808.